Evidence map›Paper›PMID 42315477›Full record

SynthesisAmerican journal of hematology2026

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

Heinz Ludwig, Evangelos Terpos, Francesca Gay, Niels W C J van de Donk, Sarah Bernhard, Monika Engelhardt, Gordon Cook, Fredrik Schjesvold, Hermann Einsele, Graham Jackson and 16 more

Abstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Heinz LudwigWilhelminen Cancer Research Institute, First Department of Medicine, Center for Oncology, Hematology and Palliative Care, Clinic Ottakring, Vienna, Austria.ORCID https://orcid.org/0000-0002-3302-8726
Evangelos TerposDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Francesca GayMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città Della Salute e Della Scienza di Torino, Torino, Italy.
Niels W C J van de DonkDepartment of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.ORCID https://orcid.org/0009-0007-1251-4649
Sarah BernhardWilhelminen Cancer Research Institute, First Department of Medicine, Center for Oncology, Hematology and Palliative Care, Clinic Ottakring, Vienna, Austria.
Monika EngelhardtDepartment of Hematology and Oncology, Interdisciplinary Cancer Center and Comprehensive Cancer Center Freiburg, University of Freiburg, Faculty of Freiburg, Freiburg, Germany.ORCID https://orcid.org/0000-0003-0405-1676
Gordon CookNIHR Leeds BRC and CRUK Clinical Trials Unit, Leeds Institute of Clinical Trial Research, Leeds, UK.
Fredrik SchjesvoldOslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.
Hermann EinseleDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Graham JacksonDepartment of Haematology, Newcastle University, Newcastle, UK.
Charlotte PawlynThe Institute of Cancer Research, London, UK.
María-Victoria MateosDepartment of Hematology, University Hospital of Salamanca/IBSAL, Salamanca, Spain.ORCID https://orcid.org/0000-0003-2390-1218
Sonja ZweegmanDepartment of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
Martin SchrederFirst Department of Medicine, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria.
Meral BeksaçDepartment of Hematology, Istinye University, Ankara Liv Hospital, Ankara, Turkey.
Christoph DriessenDepartment of Oncology/Hematology, Kantonsspital, St. Gallen, Switzerland.
Enrique M OcioServicio de Hematología y Hemoterapia, Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.ORCID https://orcid.org/0000-0002-5765-0085
Rakesh PopatNIHR/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0001-6553-4618
Leo RascheDepartment of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Cyrille TouzeauService D'hématologie Clinique, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France.
Pellegrino MustoDepartment of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy.
Annemiek BroijlDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Meletios DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Roman HajekFN Ostrava, Ostrava, Czech Republic.
Mario BoccadoroEuropean Myeloma Network (EMN), Torino, Italy.
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Funding

Austrian Forum Against Cancer
6 · The paper itself

Abstract

We performed a comprehensive review with meta- and network meta-analyzes of maintenance-therapy studies. Lenalidomide, proteasome inhibitors, and CD38 antibodies improved progression-free survival (PFS). However, overall survival (OS) benefit appeared only with lenalidomide in transplant-eligible (TE) patients, while CD38-directed therapy showed a trend toward improved OS not seen with proteasome inhibitors. The network meta-analysis ranked regimens against observation: daratumumab-lenalidomide (DR) yielded the greatest PFS benefit, followed by carfilzomib-lenalidomide-dexamethasone (KRd), KR in TE, and DRd in transplant-ineligible patients. Significant OS prolongation in TE patients occurred with KR, DR, and lenalidomide alone.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsMaintenance ChemotherapyMultiple MyelomaAntibodies, MonoclonalDexamethasoneEuropeHumansLenalidomideOligopeptidesProgression-Free SurvivalProteasome InhibitorsAntibodies, MonoclonalcarfilzomibdaratumumabDexamethasoneLenalidomideOligopeptidesProteasome Inhibitors

Identifiers

PMID42315477
PMCPMC13428405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.